Peptides
DSIP
Delta sleep-inducing peptide has small, old human insomnia experiments with weak findings; its name overstates how much reliable clinical evidence is available.
Small double-blind insomnia experiment; weak signal and no established broad clinical benefit
Also known as: Delta sleep-inducing peptide · Emideltide
Practical use
Evidence interpretation and clinical context
- Ask what sleep outcome changed
- Separate time to sleep, sleep architecture, perceived quality and daytime function.
- Check the size and date of the study
- A 16-person short laboratory experiment does not establish durable effectiveness.
- Read the authors’ conclusion
- Do not upgrade weak findings into a reliable treatment claim when the report itself is cautious.
The current FDA source is a safety discussion — primary or official source
Overview
DSIP, also called emideltide, is a research peptide investigated in sleep physiology. A substance’s name is not an efficacy result. For insomnia, the useful outcomes include perceived sleep quality and daytime function as well as laboratory sleep measurements.
Risks and limitations
The small human study cannot adequately characterize uncommon or long-term harms. FDA highlights immunogenicity, impurity and substance-characterization concerns for proposed compounded emideltide and insufficient safety information for the proposed route.
How to read this
An objective sleep measurement can change while a person does not report sleeping better. Both sides matter when judging whether an insomnia treatment provides meaningful benefit.
Research explained
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.
Who was studied
16 people with chronic insomnia in a double-blind matched-pairs parallel study conducted over five laboratory nights.
What was found
Some objective sleep-efficiency and sleep-latency measurements favored DSIP. The effects were weak and partly attributable to an incidental placebo-group change; subjective sleep quality did not improve.
What it cannot establish
The study was very small and short. Its authors did not consider the findings likely to represent major therapeutic benefit for chronic insomnia.
Read the original studyThe current FDA source is a safety discussion
Emideltide appears in the nominated-but-withdrawn section of FDA’s compounding-risk page. That entry does not confer drug approval or confirm clinical effectiveness.
Supporting sourceA statistically detectable signal can still be clinically weak
When multiple sleep measures are tested in a small sample, an isolated favorable measurement deserves caution. The trial’s own interpretation was restrained.
Supporting sourceClaims versus findings
Not established
DSIP is a clinically proven way to restore deep sleep.
The cited controlled experiment found weak objective changes without better subjective sleep quality.
Check the evidenceCommon questions
Does the phrase sleep-inducing prove the peptide helps chronic insomnia?
No. The controlled human findings and their limitations matter more than the name.
SourceSources
The current FDA source is a safety discussion — primary or official source
Sources checked 2026-10-01.
General education; not a personal treatment plan.